EXOTAC
LIVE

Serial Number

97106183

Owner

ILIAS Biologics Inc.

Attorney

Janice Housey

Filing Date

Nov 3, 2021

Add to watchlist:

No watchlists yet
View on USPTO

EXOTAC Trademark

Serial Number: 97106183 • Registration: 7459469

EXOTAC is a trademark filed by ILIAS Biologics Inc. on November 3, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ILIAS Biologics Inc. (11 trademarks)

40-20 Techno 6-ro, Yuseong-gu
Daejeon 34014 , KR

Entity Type: 03

Trademark Details

Filing Date

November 3, 2021

Registration Date

July 30, 2024

Published for Opposition

May 14, 2024

Goods & Services

Research and development of technology for biotechnology; development of pharmaceutical preparations and medicines; development of cell therapy products; research and development of new pharmaceuticals; medical research and product development services; research and development of vaccines and medicines; product development in the field of biologics; research of biologics, namely, scientific study and research in the field of biologics; laboratory research in the field of biology; industrial research in the field of biomedical engineering; technological research in the field of cell biology; scientific research in the field of pharmaceuticals; biotechnology research; biological research services; research for medical products; research in the field of chemistry; drug discovery services; biomedical research services; pharmaceutical drug development services

Biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biochemical preparations for medical or veterinary purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceuticals featuring drug delivery system, namely, pharmaceutical preparations for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary diseases; preparations for intracellular drug delivery, namely, drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injections, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations; pharmaceuticals for the treatment of immune system disease; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cellular diseases; chemico-pharmaceutical preparations for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; protein preparations, namely, protein supplements; biotechnological preparations for medical purposes for treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; reagents for medical use; pharmaceuticals for human purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biochemical pharmaceuticals for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biological tissue cultures for medical purposes; diagnostic reagents for medical use; pharmaceuticals for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases

Biological preparations, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; biological preparations for use in experiments containing exosomes carrying the desired protein, other than for medical or veterinary use; biochemical preparations for gene recombination for scientific or laboratory purposes; biological tissue cultures, other than for medical or veterinary purposes; cells for scientific or laboratory purposes; biological preparations for scientific or laboratory purposes other than for medical or veterinary use; diagnostic reagents for scientific or research use; diagnostic reagents for use in biological or genetic engineering for scientific or research use and medical laboratory use; reagents for scientific or medical research use; biological preparations for use in biotechnology industry and science, other than for medical purpose; cell growth media for growing cells for use in scientific research; biochemicals for in vitro and in vivo scientific use; reagents for medical research; biological preparation containingexosomes for use in manufacture of cosmetics; protein for use in the manufacture of cosmetics; chemical preparations for use in the manufacture of cosmetics; chemical additives for use in the manufacture of cosmetics; proteins for the food industry

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 16, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 16, 2026 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Mar 16, 2026 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 16, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 16, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 16, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 16, 2026 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 30, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 30, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 14, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 14, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 11, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 11, 2024 CRFA
ASSIGNED TO LIE
Apr 9, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 18, 2023 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 11, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 11, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 11, 2023 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 14, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 14, 2023 GNSL
SUSPENSION LETTER WRITTEN
Mar 14, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 20, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 18, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 18, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 21, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 21, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 21, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 13, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 13, 2021 NWOS
NEW APPLICATION ENTERED
Nov 6, 2021 NWAP